Cargando…
IL-17 Inhibition: A Valid Therapeutic Strategy in the Management of Hidradenitis Suppurativa
Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with a significant negative impact on the quality of life of patients. To date, the therapeutic landscape for the management of the disease has been extremely limited, resulting in a profound unmet need. Indeed, adalimumab, an anti...
Autores principales: | Malvaso, Dalma, Calabrese, Laura, Chiricozzi, Andrea, Antonelli, Flaminia, Coscarella, Giulia, Rubegni, Pietro, Peris, Ketty |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10609891/ https://www.ncbi.nlm.nih.gov/pubmed/37896210 http://dx.doi.org/10.3390/pharmaceutics15102450 |
Ejemplares similares
-
Clinical and Ultrasonographic Profile of Adalimumab-treated Hidradenitis Suppurativa Patients: A Real-life Monocentric Experience
por: CHIRICOZZI, Andrea, et al.
Publicado: (2020) -
Apremilast for the treatment of hidradenitis suppurativa associated with psoriatic arthritis in multimorbid patients: Case report and review of literature
por: Garcovich, Simone, et al.
Publicado: (2020) -
Prevalence of Neuropathic Pain and Related Characteristics in Hidradenitis Suppurativa: A Cross-Sectional Study
por: Garcovich, Simone, et al.
Publicado: (2020) -
Similar Levels of Efficacy of Two Different Maintenance Doses of Adalimumab on Clinical Severity and Quality of Life of Patients with Hidradenitis Suppurativa
por: Fania, Luca, et al.
Publicado: (2022) -
Adalimumab Originator vs. Biosimilar in Hidradenitis Suppurativa: A Multicentric Retrospective Study
por: Burlando, Martina, et al.
Publicado: (2022)